<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>8571222</pmcid><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmid">34471976</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmc">8571222</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="publisher-id">2413</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="doi">10.1007/s00702-021-02413-0</article-id></all-ids><extracted-table><table-id>Tab1</table-id><table-label>Table 1</table-label><table-caption>Descriptive statistics and comparisons between amyotrophic lateral sclerosis and healthy control groups considering the sex</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab1"><label>Table 1</label><caption><p>Descriptive statistics and comparisons between amyotrophic lateral sclerosis and healthy control groups considering the sex</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left" colspan="2">ALS</th><th align="left" colspan="2">HC</th><th align="left" colspan="4"><italic>t</italic> test (<italic>p</italic> value)</th></tr><tr><th align="left"/><th align="left">M (<italic>n</italic> = 25)</th><th align="left">F (<italic>n</italic> = 20)</th><th align="left">M (<italic>n</italic> = 15)</th><th align="left">F (<italic>n</italic> = 15)</th><th align="left">ALS-M vs. ALS-F</th><th align="left">HC-M vs. HC-F</th><th align="left">ALS-M vs. HC-M</th><th align="left">ALS-F vs. HC-F</th></tr></thead><tbody><tr><td align="left" colspan="9">Demographics</td></tr><tr><td align="left"> Age, years</td><td align="left">57.64 (10.16)</td><td align="left">57.55 (9.07)</td><td align="left">55.47 (8.05)</td><td align="left">54.93 (10.40)</td><td align="left">0.00 (0.97)</td><td align="left">0.02 (0.87)</td><td align="left">0.49 (0.48)</td><td align="left">0.62 (0.43)</td></tr><tr><td align="left"> Education, years</td><td align="left">9.59 (4.50)</td><td align="left">10.28 (4.49)</td><td align="left">13.43 (3.04)</td><td align="left">12.20 (2.95)</td><td align="left">0.23 (0.63)</td><td align="left">0.80 (0.37)</td><td align="left">4.39 (0.04)</td><td align="left">2.01 (0.16)</td></tr><tr><td align="left" colspan="9">Clinical features</td></tr><tr><td align="left">Symptom duration, months</td><td align="left">10.92 (4.44)</td><td align="left">11.60 (3.34)</td><td align="left">–</td><td align="left">–</td><td align="left">0.32 (0.57)</td><td align="left">–</td><td align="left">–</td><td align="left">–</td></tr><tr><td align="left">ALSFRS–R total score</td><td align="left">39.36 (7.18)</td><td align="left">36.55 (5.46)</td><td align="left">–</td><td align="left">–</td><td align="left">2.08 (0.15)</td><td align="left">–</td><td align="left">–</td><td align="left">–</td></tr><tr><td align="left" colspan="9">ALSFRS–R subscore</td></tr><tr><td align="left"> Bulbar</td><td align="left">10.56 (2.69)</td><td align="left">10.65 (2.32)</td><td align="left">–</td><td align="left">–</td><td align="left">0.01 (0.90)</td><td align="left">–</td><td align="left">–</td><td align="left">–</td></tr><tr><td align="left"> Fine motor</td><td align="left">8.28 (3.44)</td><td align="left">7.10 (2.98)</td><td align="left">–</td><td align="left">–</td><td align="left">1.46 (0.23)</td><td align="left">–</td><td align="left">–</td><td align="left">–</td></tr><tr><td align="left"> Gross motor</td><td align="left">9.36 (2.76)</td><td align="left">7.40 (3.51)</td><td align="left">–</td><td align="left">–</td><td align="left">4.38 (0.04)</td><td align="left">–</td><td align="left">–</td><td align="left">–</td></tr><tr><td align="left"> Respiratory</td><td align="left">11.40 (1.82)</td><td align="left">11.35 (1.13)</td><td align="left">–</td><td align="left">–</td><td align="left">0.01 (0.91)</td><td align="left">–</td><td align="left">–</td><td align="left">–</td></tr><tr><td align="left">Disease progression rate</td><td align="left">0.90 (0.83)</td><td align="left">1.06 (0.55)</td><td align="left">–</td><td align="left">–</td><td align="left">0.52 (0.47)</td><td align="left">–</td><td align="left">–</td><td align="left">–</td></tr><tr><td align="left">UMN score</td><td align="left">7.08 (4.41)</td><td align="left">8.35 (4.04)</td><td align="left">–</td><td align="left">–</td><td align="left">0.99 (0.32)</td><td align="left">–</td><td align="left">–</td><td align="left">–</td></tr><tr><td align="left" colspan="9">Cognitive measures</td></tr><tr><td align="left">MMSE</td><td align="left">27.56 (1.76)</td><td align="left">28.46 (1.03)</td><td align="left">28.60 (1.40)</td><td align="left">28.26 (1.03)</td><td align="left">2.35 (0.13)</td><td align="left">0.54 (0.46)</td><td align="left">2.96 (0.09)</td><td align="left">0.24 (0.62)</td></tr><tr><td align="left">ECAS</td><td align="left">104.49 (9.82)</td><td align="left">102.71 (10.62)</td><td align="left">–</td><td align="left">–</td><td align="left">0.21 (0.65)</td><td align="left">–</td><td align="left">–</td><td align="left">–</td></tr></tbody></table><table-wrap-foot><p><italic>ALS</italic> amyotrophic lateral sclerosis group, <italic>HC</italic> healthy control group, <italic>M</italic> male, <italic>F</italic> female, <italic>ALSFRS</italic>-R ALS functional rating scale revised, <italic>UMN</italic> upper motor neuron score, <italic>MMSE</italic> mini mental state examination, <italic>ECAS</italic> Edinburgh Cognitive and Behavioural <italic>ALS</italic> screen, significant group difference was reported in <bold>bold</bold> after Bonferroni correction: [for ALS-<italic>M</italic> vs. ALS-<italic>F</italic>: &lt; 0.01 (0.05/12), for HC-<italic>M</italic> vs. HC-<italic>F</italic> ALS-<italic>M</italic> vs. HC-<italic>M</italic> and ALS-<italic>F</italic> vs. HC-<italic>F</italic>: 0.01 (0.05/3)]</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Descriptive statistics and comparisons between amyotrophic lateral sclerosis and healthy control groups considering the sex</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left" colspan="2">ALS</th><th align="left" colspan="2">HC</th><th align="left" colspan="4">t test (p value)</th></tr><tr><th align="left"/><th align="left">M (n = 25)</th><th align="left">F (n = 20)</th><th align="left">M (n = 15)</th><th align="left">F (n = 15)</th><th align="left">ALS-M vs. ALS-F</th><th align="left">HC-M vs. HC-F</th><th align="left">ALS-M vs. HC-M</th><th align="left">ALS-F vs. HC-F</th></tr></thead><tbody><tr><td align="left" colspan="9">Demographics</td></tr><tr><td align="left"> Age, years</td><td align="left">57.64 (10.16)</td><td align="left">57.55 (9.07)</td><td align="left">55.47 (8.05)</td><td align="left">54.93 (10.40)</td><td align="left">0.00 (0.97)</td><td align="left">0.02 (0.87)</td><td align="left">0.49 (0.48)</td><td align="left">0.62 (0.43)</td></tr><tr><td align="left"> Education, years</td><td align="left">9.59 (4.50)</td><td align="left">10.28 (4.49)</td><td align="left">13.43 (3.04)</td><td align="left">12.20 (2.95)</td><td align="left">0.23 (0.63)</td><td align="left">0.80 (0.37)</td><td align="left">4.39 (0.04)</td><td align="left">2.01 (0.16)</td></tr><tr><td align="left" colspan="9">Clinical features</td></tr><tr><td align="left">Symptom duration, months</td><td align="left">10.92 (4.44)</td><td align="left">11.60 (3.34)</td><td align="left">–</td><td align="left">–</td><td align="left">0.32 (0.57)</td><td align="left">–</td><td align="left">–</td><td align="left">–</td></tr><tr><td align="left">ALSFRS–R total score</td><td align="left">39.36 (7.18)</td><td align="left">36.55 (5.46)</td><td align="left">–</td><td align="left">–</td><td align="left">2.08 (0.15)</td><td align="left">–</td><td align="left">–</td><td align="left">–</td></tr><tr><td align="left" colspan="9">ALSFRS–R subscore</td></tr><tr><td align="left"> Bulbar</td><td align="left">10.56 (2.69)</td><td align="left">10.65 (2.32)</td><td align="left">–</td><td align="left">–</td><td align="left">0.01 (0.90)</td><td align="left">–</td><td align="left">–</td><td align="left">–</td></tr><tr><td align="left"> Fine motor</td><td align="left">8.28 (3.44)</td><td align="left">7.10 (2.98)</td><td align="left">–</td><td align="left">–</td><td align="left">1.46 (0.23)</td><td align="left">–</td><td align="left">–</td><td align="left">–</td></tr><tr><td align="left"> Gross motor</td><td align="left">9.36 (2.76)</td><td align="left">7.40 (3.51)</td><td align="left">–</td><td align="left">–</td><td align="left">4.38 (0.04)</td><td align="left">–</td><td align="left">–</td><td align="left">–</td></tr><tr><td align="left"> Respiratory</td><td align="left">11.40 (1.82)</td><td align="left">11.35 (1.13)</td><td align="left">–</td><td align="left">–</td><td align="left">0.01 (0.91)</td><td align="left">–</td><td align="left">–</td><td align="left">–</td></tr><tr><td align="left">Disease progression rate</td><td align="left">0.90 (0.83)</td><td align="left">1.06 (0.55)</td><td align="left">–</td><td align="left">–</td><td align="left">0.52 (0.47)</td><td align="left">–</td><td align="left">–</td><td align="left">–</td></tr><tr><td align="left">UMN score</td><td align="left">7.08 (4.41)</td><td align="left">8.35 (4.04)</td><td align="left">–</td><td align="left">–</td><td align="left">0.99 (0.32)</td><td align="left">–</td><td align="left">–</td><td align="left">–</td></tr><tr><td align="left" colspan="9">Cognitive measures</td></tr><tr><td align="left">MMSE</td><td align="left">27.56 (1.76)</td><td align="left">28.46 (1.03)</td><td align="left">28.60 (1.40)</td><td align="left">28.26 (1.03)</td><td align="left">2.35 (0.13)</td><td align="left">0.54 (0.46)</td><td align="left">2.96 (0.09)</td><td align="left">0.24 (0.62)</td></tr><tr><td align="left">ECAS</td><td align="left">104.49 (9.82)</td><td align="left">102.71 (10.62)</td><td align="left">–</td><td align="left">–</td><td align="left">0.21 (0.65)</td><td align="left">–</td><td align="left">–</td><td align="left">–</td></tr></tbody></table></div>ALS amyotrophic lateral sclerosis group, HC healthy control group, M male, F female, ALSFRS-R ALS functional rating scale revised, UMN upper motor neuron score, MMSE mini mental state examination, ECAS Edinburgh Cognitive and Behavioural ALS screen, significant group difference was reported in bold after Bonferroni correction: [for ALS-M vs. ALS-F: &lt; 0.01 (0.05/12), for HC-M vs. HC-F ALS-M vs. HC-M and ALS-F vs. HC-F: 0.01 (0.05/3)]</transformed-table></extracted-table></extracted-tables-set>